# CEL Sci Corp: Form 10-Q for the period ended Jun 30, 2011

- Company: [CEL Sci Corp](/companies/cvm.md) (CIK 725363)
- Form: 10-Q
- Filed: 2011-08-09
- Accepted by EDGAR: Aug 9, 2011, 16:14 ET
- Period: 2011-06-30
- Accession: 0001354488-11-002531
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/725363/000135448811002531/cvm_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/725363/000135448811002531/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2011-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2011-04-01 to 2011-06-30 | $77.4k | us-gaap:Revenues |
| Revenue | 9 months, 2010-10-01 to 2011-06-30 | $784.0k | us-gaap:Revenues |
| Research and development | 3 months, 2011-04-01 to 2011-06-30 | $2.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2010-10-01 to 2011-06-30 | $9.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2011-04-01 to 2011-06-30 | −$4.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2010-10-01 to 2011-06-30 | −$14.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2011-04-01 to 2011-06-30 | −$66.2k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2010-10-01 to 2011-06-30 | −$149.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2011-04-01 to 2011-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2010-10-01 to 2011-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2011-04-01 to 2011-06-30 | −$3.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2010-10-01 to 2011-06-30 | −$23.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2011-04-01 to 2011-06-30 | −$0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2010-10-01 to 2011-06-30 | −$0.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2011-04-01 to 2011-06-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2010-10-01 to 2011-06-30 | −$0.12 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2011-04-01 to 2011-06-30 | 241,110,822 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2010-10-01 to 2011-06-30 | 206,860,979 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2010-10-01 to 2011-06-30 | −$17.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2010-10-01 to 2011-06-30 | −$175.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2011-06-30 | $10.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2011-06-30 | $15.6m | us-gaap:AssetsCurrent |
| Total assets | at 2011-06-30 | $23.7m | us-gaap:Assets |
| Current liabilities | at 2011-06-30 | $11.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2011-06-30 | $14.6m | us-gaap:Liabilities |
| Shareholders' equity | at 2011-06-30 | $9.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 21,491 characters.

#### Liquidity and Capital Resources

The Company has had only limited revenues from operations since its inception in March 1983. The Company has relied upon capital generated from the public and private offerings of its common stock and convertible notes. In addition, the Company has utilized short-term loans to meet its capital requirements. Capital raised by the Company has been expended primarily to acquire an exclusive worldwide license to use, and later purchase, certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system. Capital has also been used for patent applications, debt repayment, research and development, administrative costs, and the construction of the Company’s laboratory facilities. The Company does not anticipate realizing significant revenues until it enters into licensing arrangements regarding its technology and know-how or until it receives regulatory approval to sell its products (which could take a number of years). As a result the Company has been dependent upon the proceeds from the sale of its securities to meet all of its liquidity and capital requirements and anticipates having to do so in the future.

The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. The ability of the Company to complete the necessary clinical trials and obtain Federal Drug Administration (FDA) approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes that, counting its cash on hand and access to capital through the MLV sales agreement (see Note G to the accompanying financial statements), it has enough capital to support its operations for more than the next twelve months. The cash expenditure from the settlement will be dependent on the stock price during the next 8 months. If the stock price remains above $0.67, the conversion price of the settlement securities, it is likely that most of the settlement securities will be converted into CEL-SCI common stock and will not result in the planned cash payments. It would seem likely that a higher share price will therefore reduce the Company’s cash expenditures during the next 8 months by an amount between $0 (below $0.67 during the next 8 months) and $7 million.

The Company has two partners who have agreed to participate in and pay for part of the Phase III clinical trial for Multikine. The Company has substantial capital for its operations and can raise another $30 million under the sales agreement with McNicoll Lewis & Vlak, LLC (MLV) (see Note G to the accompanying financial statements). On December 29, 2010, the Company announced that it had commenced the Phase III clinical trial for Multikine. The net cost to the Company of the Phase III clinical trial is estimated to be $25 - $26 million.

During the nine-month period ended June 30, 2011, the Company’s cash decreased by $15,992,165. Significant components of this decrease include approximately $4 million paid towards the settlement of the lawsuit, $2 million in prepayments for the Phase III clinical trial which the Company expects to be used during fiscal year 2011 and 2012 and research and development expenses of $9.2 million. In addition, the cost of defending the lawsuit of approximately $1.2 million is included in the decrease in cash. This expense will no longer be necessary as the lawsuit has been settled. These expenses are offset by stock sales of $2.34million. This decrease is compared to a decrease in cash of $3,091,880 during the nine months ended June 30, 2010. For the nine months ended June 30, 2011 and 2010, cash used in operating activities totaled $17,724,228 and $9,064,665, respectively. For the nine months ended June 30, 2011 and 2010, cash provided by financing activities totaled $1,931,582 and $6,308,874, respectively. Cash used by investing activities was $199,519 and $336,089, for the nine months ended June 30, 2011 and 2010, respectively. The use of cash in investing activities consisted primarily of purchases of equipment and legal costs incurred in patent applications.

In August 2007, the Company leased a building near Baltimore, Maryland. The building, which consists of approximately 73,000 square feet, was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase III clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and required an annual base rent payments of $1,575,000 during the first year of the lease. The annual base rent escalates each year at 3%. The Company is also required to pay all real and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease. The lease required the Company to pay $3,150,000 towards the remodeling costs, which will be recouped by reductions in the annual base rent of $303,228 in years six through twenty of the lease. On January 24, 2008, a second amendment to the lease for the manufacturing facility was signed. In accordance with the amendment, the Company was required to pay the following: 1) an additional $518,790 for movable equipment, which increased restricted cash, and 2) an additional $1,295,528 into the escrow account to cover additional costs, which increased deferred rent. These funds were transferred in early February 2008. In April 2008, an additional $288,474 was paid toward the completion of the manufacturing facility. The Company took possession of the manufacturing facility in October of 2008. An additional $505,225 was paid for the completion of the work on the manufacturing facility in October 2008. During the nine months ended June 30, 2010, an additional $32,059 was paid for final completion costs. During the nine months ended June 30, 2011, the Company paid $21,177 as a bonus on completion to the landlord.

In December 2008, the Company was not in compliance with certain lease requirements (i.e., failure to pay an installment of Base Annual Rent). However, the landlord did not declare the Company to be in default, but instead renegotiated the lease. In January 2009, as part of an amended lease agreement on the manufacturing facility, the Company repriced the 3,000,000 warrants issued to the landlord in July 2007 at $1.25 per share which were to expire on July 12, 2013. These warrants were repriced at $0.75 per share and expire on January 26, 2014. The cost of this repricing and extension of the warrants was $70,515. In addition, 787,500 additional warrants were given to the landlord on the same date. The warrants are exercisable at a price of $0.75 per share and will expire on January 26, 2014. The cost of these warrants was $45,207. During the three months ended June 30, 2009, the Company issued the landlord an additional 2,296,875 warrants in accordance with an amendment to the lease. These warrants were issued at a price of $0.75 and will expire between March 31, 2014 and June 30, 2014. These warrants were valued at $251,172 using the Black Scholes method. The Company is currently in compliance with the lease.

Regulatory authorities prefer to see biologics such as Multikine manufactured in the same manufacturing facility for Phase III clinical trials and for the sale of the product since this arrangement helps ensure that the drug lots used to conduct the clinical trials will be consistent with those that may be subsequently sold commercially. Although some biotech companies outsource their manufacturing, this can be risky with biologics because biologics require intense manufacturing and process control. With biologic products a minor change in manufacturing and process control can result in a major change in the biological activity of the final product. Good and consistent manufacturing and process control is critical and is best assured if the product is manufactured and controlled in the manufacturer’s own facility by the Company’s own specially trained personnel.

On January 28, 2009, the Company subleased a portion of the manufacturing facility. The sublease commenced on February 2, 2009 and ended July 2010. The Company received $10,300 per month in rent for the subleased space.

#### Results of Operations and Financial Condition

During the nine months ended June 30, 2011, revenue increased by $692,536 compared to the nine months ended June 30, 2010. In November 2010, the Company received a $733,437 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA). The grant was related to three of the Company’s projects, including the Phase III trial of Multikine. The PPACA provides small and mid-sized biotech, pharmaceutical and medical device companies with up to a 50% tax credit for investments in qualified therapeutic discoveries for tax years 2009 and 2010, or a grant for the same amount tax-free. The tax credit/grant program covers research and development costs from 2009 and 2010 for all qualified “therapeutic discovery projects.” The Company recognizes revenue as the expenses are incurred. The amount of the grant earned during the nine and three months ended June 30, 2011 was $717,298 and $33,098, respectively. During the three months ended June 30, 2011, revenue increased by $46,503 compared to the three months ended June 30, 2011. The Company no longer subleases a portion of the manufacturing facility, but earns the revenue from the PPACA.

During the nine and three month periods ended June 30, 2011, research and development expenses increased by $1,497,752 and $1,337,251, respectively, compared to the nine and three-month periods ended June 30, 2010. The Company is continuing the Phase III clinical trial and research and development fluctuates based on the activity level of the clinical trial.

During the nine and three-month periods ended June 30, 2011, general and administrative expenses increased by $460,018 and $159,463, respectively, compared to the nine and three-month periods ended June 30, 2010. Fees for the ongoing lawsuit described in Item 3 of the Company’s report on Form 10-K have fluctuated over the past year. The Company spent approximately $1.2 million and approximately $539,000 defending the lawsuit during the nine and three months ended June 30, 2011. This expenditure will no longer be necessary as the lawsuit has been settled.

Interest income during the nine and three months ended June 30, 2011 decreased by $153,611 and $45,409, compared to the nine and three-month period ended June 30, 2010, respectively. The decrease was due to the decrease in the funds available for investment and lower interest rates.

The gain on derivative instruments of $2,879,003 and $1,763,311 for the nine and three months ended June 30, 2011 was the result of the change in fair value of the derivative liabilities and Series K Warrants during the period. This gain was caused by fluctuations in the share price of the Company’s common stock.

The interest expense of $149,042 and $66,238 for the nine and three months ended June 30, 2011 was primarily interest expense on the loan from the Company’s president. The interest expense of $124,206 and $41,402 for the nine and three months ended June 30, 2010 was interest on the loan from the Company’s president, offset by the final $3,282 in amortization of the loan premium in October, 2009. During the nine and three months ended June 30, 2011, interest was accrued on the convertible notes and convertible preferred shares in the amount of $24,836.

On May 16, 2011, CEL-SCI entered into an Exchange Agreement (referred to herein as the "Settlement Agreement") with thirteen hedge funds (the "plaintiffs") to settle all claims arising from a lawsuit initiated by the plaintiffs in October 2009 in the United States District Court for the Southern District of New York (the "Court"). As previously disclosed by CEL-SCI in its public filings, in August 2006 the plaintiffs (or their predecessors) purchased from CEL-SCI Series K notes convertible into CEL-SCI common stock and Series K warrants to purchase CEL-SCI common stock under financing agreements which provided the Series K notes and warrants with anti-dilution protection if CEL-SCI sold additional shares of common stock, or securities convertible into common stock, at a price below the then applicable conversion price of the notes or the exercise price of the warrants. In their lawsuit, the plaintiffs alleged that a March 2009 drug marketing and distribution agreement in which CEL-SCI sold units of common stock and warrants to an unrelated third party triggered these anti-dilution provisions, and that CEL-SCI failed to give effect to these provisions. The plaintiffs sought $30 million in actual damages, $90 million in punitive damages, the issuance of additional shares of common stock and warrants, and a reduction in the conversion price of the Series K notes and the exercise price of the Series K warrants. CEL-SCI denied the plaintiffs' allegations in the lawsuit and asserted that the 2009 agreement was a strategic transaction which did not trigger the anti-dilution provisions of the 2006 financing agreements.

Although the Company has vigorously defended the lawsuit and believed the plaintiffs' claims were without merit, the Company believes that a settlement of this lawsuit was in the best interests of the shareholders. The settlement was entered into to avoid the substantial costs of further litigation and the risk and uncertainty that the litigation entails. By ending this dispute, and ending the significant demands on the time and attention of the Company's management necessary to respond to the litigation, the Company is better able to focus on executing its ongoing Phase III clinical trial with its novel and non-toxic cancer drug Multikine.

Under the terms of the Settlement Agreement and its related agreements, the plaintiffs and CEL-SCI terminated the pending litigation and released each other from all claims each may have against the other, with certain customary exceptions. CEL-SCI agreed to make a $3 million cash payment and issue $9 million of securities to the plaintiffs. These securities consist of senior secured convertible promissory notes with an aggregate principal amount of $4.95 million and 4,050 shares of redeemable Series A Convertible Preferred Stock with an aggregate stated value of $4.05 million. The $3 million cash payment was made at the closing under the Settlement Agreement. The $9 million of securities will be redeemed through nine equal monthly installment payments of approximately $1 million each, plus interest on the notes and dividends on the shares at the rate of 8% per annum, with payments beginning on June 1, 2011 (the month of October requires no payment) and ending on March 1, 2012. As these installments of the principal amount of the notes and the stated value of the preferred shares are paid down, or as the notes or the preferred shares are converted by the holders into common stock, the initial $9 million due (plus interest and dividends) will be proportionately reduced until the notes are fully paid or converted and the preferred shares are fully redeemed or converted. CEL-SCI has pledged all of its assets as collateral for the repayment of these obligations. While the notes and preferred shares are outstanding, CEL-SCI is generally prohibited from paying dividends, incurring new debt or making any payments (other than interest) on existing debt, and is subject to certain restrictions on the transfer of its assets. The $12 million was accrued for and included in the March 31, 2011 consolidated financial statements.

The notes and the Series A preferred shares will be convertible, at the option of the holder, into CEL-SCI common stock at a fixed price of $0.67 per share. The conversion price represented the most recent consolidated closing sale price of the common stock on the NYSE AMEX at the time the settlement agreement was signed by the parties. The plaintiffs have agreed to restrictions on their ability to effect short sales of the common stock based on the number of warrants and common shares they hold, but excluding shares issuable upon the conversion of the notes and preferred shares. The plaintiffs have further agreed to permit an independent accounting firm to review their trading records every three months to confirm their compliance with these restrictions.

The parties' respective obligations under the Settlement Agreement, including CEL-SCI's obligation to pay cash and issue notes and preferred shares to the plaintiffs, were subject to obtaining the approval by the Court of an order exempting the issuance to the plaintiffs of the notes and preferred shares from registration under Section 3(a)(10) of the Securities Act of 1933. This was to permit the notes and preferred shares, and the shares of common stock issuable upon conversion thereof, to be freely tradable.

On June 17, 2011 the final settlement agreement was signed. During the three months ended June 30, 2011, the $3,000,000 cash payment required by the settlement was made. In addition, the first payment for the preferred shares, totaling $1,017,000 for 1,017 preferred shares, was made on June 17, 2011.

As a condition of the settlement agreement, all claims against the Company were dismissed. As a result, the $81,395 overpayment by one of the claimants was dismissed and the liability was written off during the three months ended June 30, 2011.

The foregoing summary of the terms of the settlement is qualified in its entirety by the detailed terms of the Settlement Agreement and the related agreements and documents which are filed as exhibits to the Company's report on Form 10-Q for the three months ended March 31, 2011.

#### Research and Development Expenses

During the nine and three-month periods ended June, 2011 and 2010, the Company’s research and development efforts involved Multikine and L.E.A.P.S.™. The table below shows the research and development expenses associated with each project during the nine and three-month periods.

|  | Nine Months Ended June 30, 2011 | 2010 | Three Months Ended June 30, 2011 | 2010 |
| --- | ---: | ---: | ---: | ---: |
| MULTIKINE | $8,846,063 | $6,823,218 | $2,813,372 | $1,434,208 |
| L.E.A.P.S. | 385,233 | 910,326 | 111,399 | 153,312 |
| TOTAL | $9,231,296 | $7,733,544 | $2,924,771 | $1,587,520 |

29

In January 2007, the Company received a “no objection” letter from the FDA indicating that it could proceed with the Phase III protocol with Multikine in head & neck cancer patients. The protocol for the Phase III clinical trial was designed to develop conclusive evidence of the safety and efficacy of Multikine in the treatment of advanced primary squamous cell carcinoma of the oral cavity. The Company had previously received a “no objection” letter from the Canadian Biologics and Genetic Therapies Directorate which enabled the Company to begin its Phase III clinical trial in Canada. The Company’s Phase III clinical trial began in December 2010 since the Company had to finish the completion and validation of its Multikine dedicated manufacturing facility.

Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company’s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company’s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

#### Critical Accounting Estimates and Policies

Management’s discussion and analysis of the Company’s financial condition and results of operations is based on its unaudited condensed consolidated financial statements. The preparation of these financial statements is based on the selection of accounting policies and the application of significant accounting estimates, some of which require management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and notes. The Company believes some of the more critical estimates and policies that affect its financial condition and results of operations are in the areas of operating leases and stock-based compensation. For more information regarding the Company’s critical accounting estimates and policies, see Part II, Item 7 of the Company’s 2010 10-K report. The application of these critical accounting policies and estimates has been discussed with the Audit Committee of the Company’s Board of Directors.

## Market risk

As filed, 152 characters.

The Company has a loan from the president that bears interest at 15%. The Company does not believe that it has any significant exposures to market risk.

## Controls and procedures

As filed, 1,667 characters.

#### Evaluation of Disclosure Controls and Procedures

Under the direction and with the participation of the Company’s management, including the Company’s Chief Executive and Chief Financial Officer, the Company has conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of June 30, 2011. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and that such information is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives. Based on the evaluation, the Chief Executive and Chief Financial Officer has concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2011.

#### Changes in Internal Control over Financial Reporting

The Company’s management, with the participation of the Chief Executive and Chief Financial Officer, has evaluated whether any change in the Company’s internal control over financial reporting occurred during the first nine months of fiscal year 2011. There was no change in the Company’s internal control over financial reporting during the nine months ended June 30, 2011.

Filed Aug 9, 2011.
Source: SEC EDGAR, the filing index for accession 0001354488-11-002531. Last ingested by Listed: Oct 24, 2026, 14:55 ET. No prices; not investment advice.
